Market Cap 1.06B
Revenue (ttm) 0.00
Net Income (ttm) -15.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,180,500
Avg Vol 1,503,058
Day's Range N/A - N/A
Shares Out 84.09M
Stochastic %K 25%
Beta 0.94
Analysts Strong Sell
Price Target $33.33

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hid...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 900 4520
Address:
901 Gateway Boulevard, Third Floor, South San Francisco, United States
MedicalDoctorInvestor
MedicalDoctorInvestor May. 23 at 7:50 PM
$CRVS 🇺🇸
0 · Reply
dwsrph1
dwsrph1 May. 23 at 5:04 PM
2 · Reply
lousjamsession
lousjamsession May. 23 at 5:59 AM
$CRVS bottom guesses?
7 · Reply
TheGunnerAB
TheGunnerAB May. 22 at 9:42 PM
$CRVS Steve Miller Band !
2 · Reply
ILikeDaStocks
ILikeDaStocks May. 22 at 8:05 PM
$CRVS Unfortunately, guessing the shorts will continue their rampage for a while yet... But MUCH to look forward to holding CRVS...and for the treatment of patients.
0 · Reply
doubleblindbets
doubleblindbets May. 22 at 7:18 PM
$CRVS I love the science behind soquelitinib. Very innovative MoA with potential to cure numerous inflammatory diseases with noninvasive oral administration and temporary dosing. This compares to current SOC in inflammatory diseases often requiring monthly biologic injection for life. Obviously, there is a lot of uncertainty. Outside cancer, we've only seen phase I. But plenty of drugs look great and fail in phase II/III so uncertainty of this sort will persist until drug is approved. I think the selloff can be explained as profit taking to lower exposure to such an early-stage company at time when selling terms are attractive. I don't think it reflects disappointment in data presented to date. I also think we are getting ready to end selloff and start accumulation period heading to EOY and 2027 catalysts.
0 · Reply
doubleblindbets
doubleblindbets May. 22 at 5:53 PM
$CRVS I'm not sure outside retail how much weight people give to seeking alpha. It's mostly op eds. I find their articles to be particularly bad in biopharma. It's just a noise publication outlet. Any reaction to the article will vanish about as fast as it came.
5 · Reply
Bainv
Bainv May. 22 at 5:18 PM
$CRVS as a former nursing student, i know nurse are not trained to be scientist. So you know wht to do when yousee a hit piece from a nurse.
1 · Reply
KingKai2020
KingKai2020 May. 22 at 4:00 PM
$CRVS if anyone on this board has a biochem, molecular science, genetics degree, etc... can one of you please get on seeking alpha and straight out the author of the hit piece. He claimed Jak2 inhibitors had no safety issues in early trials which is completely false. I know Kris Vaddi from when he was at Incyte and discovered Jakafi. There were safety issues early on and it was reported and documented. The author is trying to imply that Soq could show a clean safety profile now, like Jaks(false), but have issue in phase 2/3 trials. Funny how the guy gets called out & then has my posts blocked!
1 · Reply
KingKai2020
KingKai2020 May. 22 at 3:34 PM
$CRVS got some more Jan 20.00 calls for $1.70.
0 · Reply
Latest News on CRVS
Corvus Pharmaceuticals Transcript: Study update

May 14, 2026, 1:30 PM EDT - 9 days ago

Corvus Pharmaceuticals Transcript: Study update


Corvus Pharmaceuticals Press release: Study update

May 14, 2026, 1:30 PM EDT - 9 days ago

Corvus Pharmaceuticals Press release: Study update


Corvus Pharmaceuticals Slides: Study update

May 14, 2026, 1:30 PM EDT - 9 days ago

Corvus Pharmaceuticals Slides: Study update


Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)

2026-05-07T21:26:08.000Z - 16 days ago

Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)


Corvus Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 16 days ago

Corvus Pharmaceuticals Earnings release: Q1 2026


Corvus Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 16 days ago

Corvus Pharmaceuticals Quarterly report: Q1 2026


Corvus Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 weeks ago

Corvus Pharmaceuticals Proxy statement: Proxy filing


Corvus Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 weeks ago

Corvus Pharmaceuticals Proxy statement: Proxy filing


Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

Apr 23, 2026, 7:30 AM EDT - 4 weeks ago

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.


Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs

2026-04-17T08:45:23.000Z - 5 weeks ago

Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs


Corvus Pharmaceuticals files automatic mixed securities shelf

2026-03-13T12:08:45.000Z - 2 months ago

Corvus Pharmaceuticals files automatic mixed securities shelf


Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 2 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025


Corvus Pharmaceuticals Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 2 months ago

Corvus Pharmaceuticals Annual report: Q4 2025


Corvus Pharmaceuticals Earnings release: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 2 months ago

Corvus Pharmaceuticals Earnings release: Q4 2025


Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)

2026-03-12T20:05:16.000Z - 2 months ago

Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)


Corvus Pharmaceuticals Slides: Corporate presentation

Mar 12, 2026, 4:00 PM EDT - 2 months ago

Corvus Pharmaceuticals Slides: Corporate presentation


Corvus Pharmaceuticals Slides: Corporate presentation

Feb 25, 2026, 7:00 AM EST - 3 months ago

Corvus Pharmaceuticals Slides: Corporate presentation


Corvus Pharmaceuticals 7.9M share Secondary priced at $21.15

2026-01-22T13:40:42.000Z - 4 months ago

Corvus Pharmaceuticals 7.9M share Secondary priced at $21.15


Corvus Pharmaceuticals announces $150M common stock offering

2026-01-20T21:10:39.000Z - 4 months ago

Corvus Pharmaceuticals announces $150M common stock offering


What made Corvus stock double on Tuesday and is it sustainable?

Jan 20, 2026, 2:10 PM EST - 4 months ago

What made Corvus stock double on Tuesday and is it sustainable?


Corvus Pharmaceuticals Transcript: Study result

Jan 20, 2026, 8:00 AM EST - 4 months ago

Corvus Pharmaceuticals Transcript: Study result


Corvus Pharmaceuticals Press release: Study result

Jan 20, 2026, 8:00 AM EST - 4 months ago

Corvus Pharmaceuticals Press release: Study result


Corvus Pharmaceuticals Slides: Study result

Jan 20, 2026, 8:00 AM EST - 4 months ago

Corvus Pharmaceuticals Slides: Study result


Corvus Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2025


Corvus Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Corvus Pharmaceuticals Quarterly report: Q3 2025


Corvus Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Corvus Pharmaceuticals Earnings release: Q3 2025


Corvus Pharmaceuticals Slides: Corporate Presentation

Nov 4, 2025, 4:00 PM EST - 7 months ago

Corvus Pharmaceuticals Slides: Corporate Presentation


Corvus Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2025


Corvus Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Corvus Pharmaceuticals Quarterly report: Q2 2025


Corvus Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Corvus Pharmaceuticals Earnings release: Q2 2025


Corvus Pharmaceuticals Slides: Corporate Presentation

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Slides: Corporate Presentation


Corvus Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2025


Corvus Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Quarterly report: Q1 2025


Corvus Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings release: Q1 2025


Corvus Pharmaceuticals Slides: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Slides: Q1 2025


Corvus Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Proxy statement: Proxy Filing


Corvus Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Proxy statement: Proxy Filing


Corvus Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2024


Corvus Pharmaceuticals Annual report: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Annual report: Q4 2024


Corvus Pharmaceuticals Earnings release: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings release: Q4 2024


Corvus Pharmaceuticals Slides: FY 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Corvus Pharmaceuticals Slides: FY 2025


Corvus Pharmaceuticals Transcript: Study Update

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Transcript: Study Update


Corvus Pharmaceuticals Press release: Study Update

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Press release: Study Update


Corvus Pharmaceuticals Slides: Study Update

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Slides: Study Update


Corvus Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2024


Corvus Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Quarterly report: Q3 2024


Corvus Pharmaceuticals Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Earnings release: Q3 2024


Corvus Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2024


Corvus Pharmaceuticals Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Quarterly report: Q2 2024


Corvus Pharmaceuticals Earnings release: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings release: Q2 2024


Corvus Pharmaceuticals Earnings Call Transcript: Q1 2024

May 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2024


Corvus Pharmaceuticals Quarterly report: Q1 2024

May 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Quarterly report: Q1 2024


Corvus Pharmaceuticals Earnings release: Q1 2024

May 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings release: Q1 2024


MedicalDoctorInvestor
MedicalDoctorInvestor May. 23 at 7:50 PM
$CRVS 🇺🇸
0 · Reply
dwsrph1
dwsrph1 May. 23 at 5:04 PM
2 · Reply
lousjamsession
lousjamsession May. 23 at 5:59 AM
$CRVS bottom guesses?
7 · Reply
TheGunnerAB
TheGunnerAB May. 22 at 9:42 PM
$CRVS Steve Miller Band !
2 · Reply
ILikeDaStocks
ILikeDaStocks May. 22 at 8:05 PM
$CRVS Unfortunately, guessing the shorts will continue their rampage for a while yet... But MUCH to look forward to holding CRVS...and for the treatment of patients.
0 · Reply
doubleblindbets
doubleblindbets May. 22 at 7:18 PM
$CRVS I love the science behind soquelitinib. Very innovative MoA with potential to cure numerous inflammatory diseases with noninvasive oral administration and temporary dosing. This compares to current SOC in inflammatory diseases often requiring monthly biologic injection for life. Obviously, there is a lot of uncertainty. Outside cancer, we've only seen phase I. But plenty of drugs look great and fail in phase II/III so uncertainty of this sort will persist until drug is approved. I think the selloff can be explained as profit taking to lower exposure to such an early-stage company at time when selling terms are attractive. I don't think it reflects disappointment in data presented to date. I also think we are getting ready to end selloff and start accumulation period heading to EOY and 2027 catalysts.
0 · Reply
doubleblindbets
doubleblindbets May. 22 at 5:53 PM
$CRVS I'm not sure outside retail how much weight people give to seeking alpha. It's mostly op eds. I find their articles to be particularly bad in biopharma. It's just a noise publication outlet. Any reaction to the article will vanish about as fast as it came.
5 · Reply
Bainv
Bainv May. 22 at 5:18 PM
$CRVS as a former nursing student, i know nurse are not trained to be scientist. So you know wht to do when yousee a hit piece from a nurse.
1 · Reply
KingKai2020
KingKai2020 May. 22 at 4:00 PM
$CRVS if anyone on this board has a biochem, molecular science, genetics degree, etc... can one of you please get on seeking alpha and straight out the author of the hit piece. He claimed Jak2 inhibitors had no safety issues in early trials which is completely false. I know Kris Vaddi from when he was at Incyte and discovered Jakafi. There were safety issues early on and it was reported and documented. The author is trying to imply that Soq could show a clean safety profile now, like Jaks(false), but have issue in phase 2/3 trials. Funny how the guy gets called out & then has my posts blocked!
1 · Reply
KingKai2020
KingKai2020 May. 22 at 3:34 PM
$CRVS got some more Jan 20.00 calls for $1.70.
0 · Reply
tradingjunk321
tradingjunk321 May. 22 at 3:27 PM
$CRVS link above Phelps post. https://www.dermatologytimes.com/view/itk-inhibition-with-soquelitinib-yields-sustained-skin-clearance-up-to-90-days-off-therapy
1 · Reply
JJenniferr
JJenniferr May. 22 at 2:41 PM
$CRVS be patient
0 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor May. 22 at 2:32 PM
$CRVS wow! The fools should have exited after that last rally. Next stop, the poor house! Lost your chance. Next time listen to the doc! The doc knows best
0 · Reply
doubleblindbets
doubleblindbets May. 22 at 2:25 PM
$CRVS A healthy pullback would be welcome to support a bigger move up IMO.
0 · Reply
Shadow2013
Shadow2013 May. 22 at 4:47 AM
$CRVS all aboard
1 · Reply
Jellysquid1
Jellysquid1 May. 21 at 11:28 PM
$CRVS Another Nonsense Post Below 👇 👇👇👇 ( only 3 people following)
1 · Reply
Mr_Predicto
Mr_Predicto May. 21 at 10:34 PM
$CRVS I had to hop back on the "inverse" bandwagon today. I'm disappointed by the "fool me once, shame on you, fool me twice shame on me" action that is evolving here. I guess fool me (shareholders) twice it shall be. Here we go Ahhh.....Ghhheeen. Yup, that's right folks, we are going to re-hash Phase 1 data at annnothhher conference again. It never gets old. Hmm, I wonder what happened last time? 🤔 Hey, don't fret, it will be ok. Why? * - Your boss man bought enough shares to pay for a few beers. * - Everyone knows the NEXT conference will reveal new and exciting data this time around (🤡). * - Somebody needs to provide exit liquidity; it might as well be you. This can be your public service. * - I'm short now, so at least you will have a punching bag to vent your frustration while you lose money. Prediction: Crystal ball please show us a premonition of the next conference.
1 · Reply
Jellysquid1
Jellysquid1 May. 21 at 8:19 PM
$CRVS Well I Guess Miller Made Even More money with his Buy the other day! You should have Bought Too!
2 · Reply
KingKai2020
KingKai2020 May. 21 at 7:41 PM
$CRVS buying more jan $20 calls.
1 · Reply
tradingjunk321
tradingjunk321 May. 21 at 6:28 PM
$CRVS Just maybe we get another insider purchase today, what is a few nickels when you are looking for major dollars? 🤔
2 · Reply
KingKai2020
KingKai2020 May. 21 at 6:20 PM
$CRVS "the nurse" put out another hit piece on $CRVS on seeking alpha. I see that he is getting grilled and can't back up any of his claims which is pretty funny. I love it when a so called "analyst" does not understand the basic science behind Soq.
2 · Reply
tradingjunk321
tradingjunk321 May. 21 at 3:33 PM
$CRVS Miller "we got something here & I don't know what it will take the market to take notice, but I'm committed". He said that about 2-3 years ago, how much percentage are we up since then? 😂 I'm not complaining!
2 · Reply